News & Articles

Crossover Financing to Advance Clinical Development of Central Nervous System Assets in Migraine, Parkinson’s Disease and Acute Agitation SEATTLE, December 6th, 2018 — Impel NeuroPharma (“Impel” or the “Company”), a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (“CNS”) disorders with unmet medical needs,...

Our Impel team will be attending Piper Jaffray's 19th Annual  Health Care Conference in New York on November 27 - 29. Management teams from nearly 300 leading public and private companies in biotechnology, specialty pharmaceuticals, drug discovery, medical technology, medical diagnostics and devices, and health care services sectors will give presentations...

SEATTLE, Nov. 7, 2018 /PRNewswire/ -- Impel NeuroPharma, a Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system (CNS) disorders with unmet medical needs, today announced the appointment of Ellen A. Lubman as Chief Business Officer. In her role, Ellen's primary responsibilities are to...

The Impel team will be attending the 2018 Scottsdale Headache Symposium in Scottsdale, AZ on 15 November. Our team will be made up of Steve Shrewsbury, CMO; Ellen Lubman, CBO; Maria Jeleva, Associate Director of Clinical Operations; and Sutapa Ray, Business Development Manager. For more information, visit the event webpage here.  ...

Our CMO, Dr. Stephen Shrewbury, is presenting at the Outsourcing in Clinical Trials Pacific Northwest 2018 conference in Vancouver, Canada. Dr. Shrewbury will be giving a keynote presentation on Home Advantage: Assessing the Pacific Northwest’s competitive landscape to underpin and sustain your competitive advantage. His presentation will be on 16 October at 8:30 am. Dr. Shrewsbury will...

September 24, 2018 -- Thank you to everyone at Impel who gave their time to United Way of King County’s Day of Caring last Friday. The team volunteered to help spruce up B.F. Day Elementary in Fremont for a new school year. In only one day, an extraordinary 10,500 volunteers lent a hand...

Study to Establish Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Olanzapine Delivered via Precision Olfactory Delivery (POD®) Device SEATTLE, August 29, 2018 — Impel NeuroPharma, a Seattle-based, privately-held biopharmaceutical company focused on therapies for the treatment of central nervous system (CNS) disorders, today announced the first subject has been dosed in a...

August 27, 2018 Abstract Objectives: Primary: Compare the safety and tolerability of intranasal INP103 to placebo in patients with PD during an OFF episode. Secondary: Characterize the PK of single ascending doses of INP103; Explore the effect of single ascending doses of INP103 versus placebo on motor function and PK/pharmacodynamic relationship of...

August 24, 2008 -- In 2008, Dr. John Hoekman was a Ph.D. student in pharmaceutics who had just won a UW business plan competition and was granted $25,000 to start his company. It’s been ten years since the incorporation of Impel in 2008, and we’ve grown from just three devoted dreamers to...